Mortality Risk factors and SOX2 and mTOR expression in Patients with Esophageal Cancer

Gao Yu*, Yang Yuexin, Lv Yin, Zhang Yiyin, Kang Mei, Zhu Liyang, Xu Lei, Wang Fan
Department of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Shushan District, Hefei City, Anhui Province, China.

ARTICLE INFO

Original paper
Article history:
Received: September 15, 2021
Accepted: November 18, 2021
Published: December 01, 2021

Keywords:
Cancer-specific Mortality,
Cardiovascular Mortality Risk factors, Esophageal Cancer

ABSTRACT

Causes of mortality in EC patients are not confined to cancer-specific mortality but include various protein expressions of SOX2 and mTOR in Esophageal Cancer patients and their correlation with the clinical stage. Data about the risk factors and involvement of cancer-specific protein are still lacking. This study aimed to define the risk factors and association of SOX2 and mTOR expression in mortality in patients with EC. We conducted a retrospective cohort study to assess the risk factors for cancer-specific mortality and cardiovascular mortality in patients with esophageal cancer (EC). The expression rates of SOX2, as well as MTO, were checked in patients. The multivariate analysis revealed a high-risk EC mortality with age ≥ 65 years, grade, stage, and sequence of treatment; radiation after surgery; radiation before and after surgery; Surgery both before and after radiation. While the cardiovascular mortality increased with age ≥ 65 years, grade, stage, and sequence of treatment. The expression rates of SOX2, as well as mTOR, were 75.5 percent and 86.8 percent in Esophageal Cancer tissues, which was statistically significant (P<0.05). Risk factors for cancer-specific mortality and cardiovascular mortality in EC patients include older age at diagnosis, male sex, non-married status, grade III of the tumor, the regional or distant spread of the tumor, no cancer-directed therapy. The expression levels of SOX2, mTOR, and the total survival time were related to the different stages. It shows an upward trend for the expression levels of mTOR and SOX2 in Esophageal Cancer tissues. The expression levels of SOX2 and mTOR are related to the clinical stage, metastasis, and prognosis.

DOI: http://dx.doi.org/10.14715/cmb/2021.67.4.40
Copyright: © 2021 by the C.M.B. Association. All rights reserved.

Introduction

Esophageal cancer (EC) is one of the most common and fatal cancers (1). In 2018, more than 572,000 new cases and 508,000 deaths of EC occurred, representing about 3.2% of the new cancer cases and 5.3% of cancer deaths globally. EC is the sixth commonest cause for cancer-specific mortality (2, 3). EC prognosis is related to its stage at diagnosis, but it is usually diagnosed at late stages due to its aggressive nature and the lack of a reliable screening method (4). EC five-year survival rate ranges from 15% to 25% (5), but in the case of early diagnosis, the five-year survival rate exceeds 80% (6).

Histologically, EC is classified into squamous cell carcinoma SCC, adenocarcinoma and other less common subtypes as sarcomas, melanomas, carcinoids, lymphomas, and small cell carcinomas (7). The prevalence of EC and its subtypes vary widely across different geographic regions (8). SCC is the predominant histological type worldwide, especially in China and other Asian countries. However, adenocarcinoma predominates in the USA and western Europe, moving SCC to the second position (2, 8). The relative control of SCC risk factors may be responsible for the predominance of adenocarcinoma in western countries (9). In contrast, the incidence of adenocarcinoma is increasing with the increase of its risk factors in recent decades (10, 11).

Risk factors for SCC include mainly smoking and alcohol consumption with other less evident factors including hot beverages as tea and coffee, genetic factors and low socioeconomic level (12). Men are three times more liable to SCC than women (13). SCC is more frequent than adenocarcinoma in black people and white women, while adenocarcinoma is more frequent in white men (14). Risk factors for adenocarcinoma include gastroesophageal reflux disease GERD, obesity and tobacco smoking (12).
cases of GERD, adenocarcinoma usually develops on top of Barrett's esophagus, which is pre-neoplastic columnar metaplasia of the esophageal epithelium that occurs in about 5% to 8% of GERD patients (15, 16). Barrett's esophagus patients develop adenocarcinoma with an annual rate of about 0.5% (17). Adenocarcinoma is eight times more incident in men than in women and five times in whites than in blacks in the USA (12). Now, although there is no specific study on the pathological characteristics of esophageal cancer patients and SOX2 and mTOR, there are reports on the immunolocalization of AQPs in the intact and early degenerative regions of human knee cartilage.

Causes of mortality in EC patients are not confined to cancer-specific mortality but include circulatory, digestive, and respiratory causes (18, 19). Data about the risk factors for cancer-specific and cardiovascular mortality are still lacking. This study aimed to define the risk factors associated with cancer-specific mortality and cardiovascular mortality in patients with EC.

Materials and methods

Study Population

Based on the Surveillance, Epidemiology, and End Results SEER database, we conducted this retrospective cohort study in patients with EC. We extracted the data of all types of EC, including the treatment field from 1975 to 2016, using the SEER*Stat version 8.3.8.

Information Collection

We executed these outcomes from the SEER database; I cancer-specific mortality, II cardiovascular mortality including atherosclerosis, cerebrovascular disorders, aortic aneurysm with dissection, hypertension without heart disease, and the diseases of the heart, the arteries, the capillaries and the arterioles, III survivors. Also, We gathered these variables to estimate the risk factor of mortality; I age at diagnosis, II sex, III race, including white, black and others American Indian / Alaska Native, Asian or Pacific Islander, IV marital status, including single, married and others separated, divorced, widowed, unmarried or domestic partner, V type, including SCC, adenocarcinoma and others uncommon types, VI the primary site, including the upper, middle, lower third of the esophagus, VII grade, including I, II, III and IV, VIII stage, including localized, regional and distant, IX treatment field, including chemotherapy, surgery and radiation, X Sequence, including radiation before surgery, radiation after surgery, radiation both before and after surgery, surgery both before and after radiation and no radiation and/or cancer-directed surgery.

Detection of SOX2 and mTOR expression by qPCR

The SOX2 and mTOR expression were detected by qRT-PCR. Total RNA in the joint fluid was extracted and dissolved in 20 μL DEPC water in view of Trizol reagent operation instructions. It was reversely transcribed using a reverse transcription kit: M-MLV 1 μl, Olig (d T) 1 μl, RNA enzyme inhibitor 0.5 μl, d NTPs 1 μl, RNase free water added to 15 μl. It was cultivated at 38°C for 60 min. We took 1 μl c DNA, 85°C for 5 s; the synthesized c DNA was used as a template for qRT-PCR amplification. PCR reaction system was prepared: 10×PCR buffer 2.5 μl, d NTPs 1 μl, upstream and downstream primers 1 μl each, Taq DNA Polymerase 0.25 μl, dd H2O added to 25 μl; the conditions were as below: pre-denaturation at 95°C for 15 min, denaturation at 95°C for 15 s, annealing at 60°C for 30 s, a total of 35 cycles, extension at 72°C for 15 min. Three multiple wells were supplied for 3 repeated tests, and SOX2 and mTOR took U6 as the internal reference. Afterward, the amplification and melting curves of Real-Time PCR were confirmed, and the relative amount of the target gene was counted in the light of the result parameters. The relative quantification of the target gene was assessed by $2^{-ΔΔCt}$.

Statistical analysis

All data were statistically analyzed by SPSS 17.0 (Beijing Bizinsight Information Technology Co., Ltd.). The counting data between the two groups were tested by $\chi^2$ test. The measurement data were expressed as (x±s) and compared by independent-samples T-test. The diagnostic value of SOX2 and mTOR for esophageal cancer was evaluated by the ROC curve. The logistic regression model was established with the two as independent variables. The area under the ROC curve of joint detection was fitted by the probability value in the model. P<0.05 was
seen as a statistically remarkable difference. We analyzed the variables as univariate and multivariate using proportional hazards regression. The relationships among categorical variables were observed using Pearson’s chi-square test. The P-value of less than 0.05 means the analysis showed a significant difference.

Results

Clinicopathologic Characteristics

We listed an overall 29,084 patients with EC in our cohort study, with a mean age of 63.84 years. All general data of patients were compared, and the differences of age, gender, smoking, drinking, medical history, registered permanent residence and educational background between them were not statistically obvious. The total survival patients, EC mortality and cardiovascular mortality were 4015 13.80%, 19770 67.97% and 1367 4.70%, respectively. The chi-square of all variables showed significant difference, P < 0.001, except gender, were non-significant, P = 0.811. The clinicopathologic features of included patients are shown in Table 1.

Cancer-specific mortality

The HR of EC mortality increased in patients with age ≥ 65 years 1.158, black race 1.191, American Indian and Asian race 1.108, uncommon cancers 1.054, grade II 1.103, grade III 1.314, grade IV 1.314, regional stage 1.185 and distant stage 2.083. Cancer-specific mortality decreased in married patients 0.822 times, adenocarcinoma type 0.881 times, cancer site on the lower third of esophagus 0.917 times, patients underwent chemotherapy 0.678 times, radiation 0.76 times, Surgery 0.512 times, radiation before surgery 0.671 times and radiation both before and after surgery 0.542 times (Table 2). The multivariate analysis presented that the risk of EC mortality decreased with female HR, 0.923; 95% CI, 0.889-0.959, married states HR, 0.909; 95% CI, 0.872-0.947, adenocarcinoma type HR, 0.912; 95% CI, 0.877-0.949 and treatment field surgery: HR, 0.383; 95% CI, 0.365-0.402; chemotherapy: HR, 0.5; 95% CI, 0.483-0.518; radiation: HR, 0.743; 95% CI, 0.716-0.772 (Table 2).

The risk of mortality caused by cardiovascular diseases increased in patients with age ≥ 65 years, adenocarcinoma type, grade II, III, regional and distant stage, 1.308, 1.123, 1.398, 1.481, 1.366 and 2.415 times, respectively. The cardiovascular mortality reduced in female patients, married states, tumor site on the lower third of esophagus, patients underwent surgery, radiation before surgery, radiation after surgery and radiation both before and after surgery, 0.856, 0.829, 0.739, 0.467, 0.706, 0.696 and 0.522 times, respectively (Table 2). The risk of cardiovascular mortality of EC patients increased with age ≥ 65 years HR, 1.377; 95% CI, 1.219-1.556, adenocarcinoma type HR, 1.154; 95% CI, 1.001-1.331, grade II: HR, 1.247; 95% CI, 1.029-1.512; III: HR, 1.252; 95% CI, 1.029-1.522, stage regional: HR, 1.579; 95% CI, 1.393-1.791; distant: HR, 2.004; 95% CI, 1.687-2.381 and sequence of treatment radiation prior to surgery: HR, 3.14; 95% CI, 2.422-4.07; radiation after surgery: HR, 2.201; 95% CI, 1.687-2.873; radiation before and after surgery: HR, 1.987; 95% CI, 1.026-3.85. The factors associated with low risk of cardiovascular mortality was female patients HR, 0.779; 95% CI, 0.672-0.903, married states HR, 0.779; 95% CI, 0.676-0.945 and treatment with chemotherapy HR, 0.508; 95% CI, 0.436-0.592, radiation HR, 0.532; 95% CI, 0.441-0.641 and surgery HR, 0.208; 95% CI, 0.17-0.255 (Table 2).

Expression of SOX2 and mTOR

The attending physician divided the patients into a good prognosis group (Group A, 40 cases) and a poor prognosis group (Group B, 20 cases) according to the statistics of esophageal Cancer patients after treatment. The SOX2 and mTOR expression levels of group B were higher than those in group B, with statistically significant differences (P<0.001). The high expression rates of SOX2 and mTOR protein in esophageal cancer were more in Group B with poor diagnosis and prognosis. Briefly, the high expression...
rates of SOX2 and mTOR in esophageal cancer were prominently higher in the control group with $\chi^2$ Value higher than 25 in both cases and p-value lower than 0.001 (Table 3).

**Table 3.** Comparison of expressions of mTOR and SOX2 in osteosarcoma as well as esophageal Cancer

|          | SOX2 | mTOR |
|----------|------|------|
|          | High expression | Low expression | High expression | Low expression |
| Group A  | 7     | 33    | 6     | 34     |
| (n=40)   |       |       |       |        |
| Group B  | 13    | 7     | 14    | 6      |
| (n=20)   |       |       |       |        |
| $\chi^2$ | 25.89 |       | 28.143 |       |
| **P**    | <0.001 |     | <0.001 |     |

The Relationship between the Expression Level of SOX2 and mTOR with clinicopathological Features in esophageal cancer

The SOX2 and mTOR levels of patients were not related to the age, gender, and location of esophageal Cancer patients, but tied to the disease stage and grade. No diversity in the expression level of SOX2 and mTOR protein in patients with different genders, ages, and histology (Table 4) (P>0.05). The expression rate of mTOR and SOX2 varied depending upon the clinical stage, which was prominently lower in and statistical significance (P< 0.05).

**Table 4.** Association between the expression level of SOX2 and mTOR to characteristics of various clinical cases

| Pathological features | SOX2 | mTOR |
|-----------------------|------|------|
|                       | High expression | Low expression | High expression | Low expression |
| Gender                | 3.23 | 0.137 | 2.172 | 0.759 |
| Male                  | 11   | 23    | 12    | 22    |
| Female                | 9    | 17    | 8     | 18    |
| Age                   | 2.958 | 0.138 | 1.322 | 0.781 |
| >14                   | 12   | 24    | 13    | 25    |
| ≤14                   | 8    | 16    | 7     | 5     |
| Clinical Stage        | 33.581 | <0.001 | 13.799 | <0.001 |
| Phase A               | 15   | 32    | 14    | 31    |
| Phase B               | 5    | 8     | 6     | 9     |
| Ability to transfer w | 18.56 | <0.001 | 12.162 | 0.008 |
| Yes                   | 16   | 30    | 15    | 29    |
| No                    | 4    | 10    | 5     | 11    |

Diagnostic and predictive value of SOX2 and mTOR in the prognosis of esophageal cancer

Details of univariate analysis are shown in Figures 1 and 2 shows details of multivariate analysis. As to esophageal Cancer patients, the sensitivity, specificity, and AUC of SOX2 and mTOR single diagnosis were 78.75%, 82.14% and 0.863, respectively; the sensitivity, specificity, and AUC values of mTOR single diagnosis were 83.75%, 82.14% and 0.902, respectively. Logistic univariate analysis of risk factors associated with esophageal Cancer metastasis in those patients revealed that there were remarkable differences between patients with poor prognosis and those with good prognosis in terms of disease stage, joint function grade, timely treatment, SOX2 and mTOR (P<0.001). Their disease stage, timely treatment, SOX2 and mTOR were all tied to the prognosis of esophageal cancer and were the risk factors for its prognosis (Figs 1 and 2).

Our analysis included 29,084 EC patients, of whom 19,770 (67.97%) died of cancer-specific causes, and 1367 died of cardiovascular causes. Our results showed that risk factors for cancer-specific mortality and cardiovascular mortality in patients with EC include the age of 65 years or older at diagnosis, advanced grades of the tumor, and regional or distant
spread of the tumor. Protective factors include female sex, married status, chemotherapy, radiotherapy, and surgery. Black race versus white is a risk factor for cancer-specific but not cardiovascular mortality. Adenocarcinoma versus SCC is a risk factor for cardiovascular but protects against cancer-specific mortality. Regarding the sequence of therapy, we found that radiation before surgery, radiation after surgery and radiation before and after surgery have higher risks for cancer-specific mortality and cardiovascular mortality.

Figure 1. The survival curve for cancer-specific mortality.

Figure 2. The survival curve for cardiovascular mortality.

Previous studies support the link between advanced age at diagnosis and higher all-cause mortality trends (20, 21) and cardiovascular-specific mortality (22). On the other hand, a recent SEER-based study found that age less than 35 years at diagnosis is associated with higher cardiovascular mortality in cancer patients. However, the study included 28 cancer types, and the results were less representative for EC patients in favor of representing the more common cancer types, especially breast, prostate and bladder cancers that made up most cardiovascular deaths (23). Female sex is associated with lower risks of cancer-specific and cardiovascular mortality in our analysis. Previous studies found that women have more prolonged cancer-specific survival than men (21, 24-26). However, an earlier SEER-based study found no association between sex and cardiovascular mortality. They included the sex variable in the univariate analysis but not included in the multivariate analysis (22).

Regarding cancer differentiation, our results showed that grades III and IV increase the risk of cancer-specific mortality, while grades II and III increase the risk of cardiovascular mortality. Previous studies support the finding that higher grades of the disease are associated with increased mortality risk and lower survival rates (20, 27). However, Rouvelas et al. 2005 revealed that tumor histological variety and histological differentiation are insignificant factors of mortality after surgery (25). This may be because their selected sample was operable and underwent resection surgery, so the prognosis after surgery was less dependent on the histological type and differentiation (25). Earlier studies reported the harmful effect of thorax-directed radiation on the heart (22, 28). They stated that radiotherapy is associated with an increased risk of cardiac toxicity and cardiac death in EC patients (22, 28). In addition, a recent study by Hayashi et al. 2019 stated that these harmful effects are dependent on the level of radiation received by the heart (29). Thus, recent modulations of radiotherapy that adjust the dose and spare the heart may be the cause of our insignificant result (30, 31).

We found no association between tumor site and risk of cancer-specific or cardiovascular mortality. An earlier study found no association between tumor size and mortality in EC patients after surgery (25). On the other hand, the study by Li et al. 2009 on patients with SCC of thoracic esophagus who underwent curative esophagectomy stated that the upper third cancer site is associated with a lower survival rate (27). Other studies found that the lower third cancer site is associated with a higher risk of mortality and cardiovascular mortality (20, 28). This point of disagreement may be related to the surgical procedure
in the study by Li et al. 2009 or more radiation doses directed to the heart in the lower third tumor in the other two studies (20, 27, 28). Amin et al. 2016 found no association between EC-specific mortality with age, race, sex, marital status, size, grade, stage, histological type, and treatment. These insignificant results may be due to their selected sample that included patients with cancer confined to the intraepithelial and mucosal layers only (32). In this regard, further investigation for gene polymorphism (33-37) and a genome-wide association study (38) seem necessary.

We tested SOX2 and mTOR expression differences in esophageal cancer patients and healthy people via qRT-PCR. We found that the SOX2 and mTOR levels in group A were lower than those in group B. AQPs and Toll-like receptors (TLR) affect the biological function of pro-inflammatory cells in related inflammatory diseases, thus affecting the development of arthritis diseases. We believe that SOX2 and mTOR expression with esophageal Cancer is tied to the disease stage and joint function grade of esophageal Cancer. Subsequently, we evaluated SOX2 and mTOR’s diagnostic value in esophageal Cancer and its predictive value and found that SOX2 and has good sensitivity and specificity in diagnosing those patients after drawing ROC curves. Logistic univariate analysis and factor analysis revealed that timely treatment, SOX2 and mTOR, were independent risk factors for the prognosis of esophageal cancer patients. However, there has been no previous study on the diagnostic efficacy and predictive value of SOX2 and mTOR expression changes in their joint fluid. SOX2 and mTOR have certain predictive values for the diagnosis and prognosis of esophageal Cancer metastasis patients.

This study relies on high-quality data registered on the SEER database. These data have the advantages of reliable follow-up information and death-related information of EC patients. The results of such an amount of reliable data are more generalizable. In addition, we included many variables that may have affected cancer-specific and cardiovascular mortality. We analyzed data in both univariate and multivariate methods. However, we still have some limitations. Genetic and personal factors that might have affected cancer-specific mortality and cardiovascular mortality are not specified. Besides, different stages of localized malignancy are not distinguished.

Conclusion
Risk factors for cancer-specific mortality in EC patients include older age at diagnosis, male sex, black race, non-married status, grade III or IV of the tumors, the regional or distant spread of the tumor, no cancer-directed therapy. Risk factors for cardiovascular mortality in EC patients include older age at diagnosis, male sex, non-married status, grade II and III of the tumors, Adenocarcinoma subtype, the regional or distant spread of the tumor, no cancer-directed therapy.

References
1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet London, England. 2013; 3 819 864: 400-12. https://doi.org/10.1016/S0140-6736(12)60643-6
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cnc J Clin. 2018; 686: 394–424. https://doi.org/10.3322/caac.21492
3. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF. The Global Burden of Cancer 2013. JAMA Oncology. 2015; 14:505-27. https://doi.org/10.1001/jamaoncol.2015.0735
4. Cowie A, Noble F, Underwood T. Strategies to improve outcomes in esophageal adenocarcinoma. Exp Rev Anticanc Ther. 2014; 146:677–87. https://doi.org/10.1586/14737140.2014.895668
5. Enzinger PC, Mayer RJ. Esophageal cancer. The New Eng J med. 2003; 34923:2241-52. https://doi.org/10.1056/NEJMra035010
6. Wang GQ, Jiao GG, Chang FB, et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. The An Thor Sur. 2004; 775: 1740–4. https://doi.org/10.1016/j.athoracsur.2003.10.098
7. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Col Sur. 2000; 1905:562-72; discussion 72-3. https://doi.org/10.1016/S1072-7515(00)00238-6
8. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015; 64:381–7. https://doi.org/10.1136/gutjnl-2014-308124

9. Castro C, Bosetti C, Malvezzi M, et al. Patterns and trends in esophageal cancer mortality and incidence in Europe 1980-2011 and predictions to 2015. An Oncolo. 2014; 251:283–90. https://doi.org/10.1093/annonc/mdt486

10. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 1196:1149-58. https://doi.org/10.1002/j.suc.2012.07.008

11. Bilal I, Xie S, Elburki M, Aziziaram Z, Ahmed S, Jalal Balaky S. Cytotoxic effect of diferuloylmethane, a derivative of turmeric on different human glioblastoma cell lines. Cell Mol Biomed Rep 2021; 1(1): 14-22.

12. Wheeler JB, Reed CE. Epidemiology of esophageal cancer. The Sur clin North Am. 2012; 925:1077-87. https://doi.org/10.1016/j.suc.2012.07.008

13. Gupta B, Kumar N. Worldwide incidence, mortality, and time trends for cancer of the esophagus. Eur J Can Preven. 2017; 262:107–18. https://doi.org/10.1097/CEJ.0000000000000249

14. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013; 1934:5598–606. https://doi.org/10.3748/wjg.v19.i34.5598

15. Romero Y, Cameron AJ, Schaid DJ, et al. Barrett’s esophagus: prevalence in symptomatic relatives. Am J Gastroenterol. 2002; 975:1127-32. https://doi.org/10.1111/j.1572-0241.2002.05665.x

16. Thrift AP. Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? Diges Dis Sci. 2018; 638:1988–96. https://doi.org/10.1007/s10620-018-5068-6

17. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. Jama. 2002; 28 715:1972–81. https://doi.org/10.1001/jama.287.15.1972

18. Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut. 2018; 673:418-529. https://doi.org/10.1136/gutjnl-2016-312223

19. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterol. 2013;1447:1375-83, 83.e1. https://doi.org/10.1053/j.gastro.2013.02.050

20. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002; 957:1434-43. https://doi.org/10.1002/cncr.10868

21. Ilic M, Kocic S, Radovanovic D, Zivanovic Macuzic I, Ilic I. Trend in esophageal cancer mortality in Serbia, 1991-2015 a population- based study: an age-period-cohort analysis and a jointpoint regression analysis. J BUON.2019;243:1233–9.

22. Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointestinal Oncol. 2015; 65:516-23.

23. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur heart J. 2019; 4048:3889–97. https://doi.org/10.1093/eurheartj/ehz766

24. Bohanes P, Yang D, Chhibar RS, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012; 3018:2265-72. https://doi.org/10.1200/JCO.2011.38.8751

25. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. The Lancet Oncol. 2005; 611:864-70. https://doi.org/10.1016/S1470-2045(05)70347-8

26. Trivers KF, De Roos AJ, Gammon MD, et al. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol. 2005; 33:225–30. https://doi.org/10.1016/S1542-3565(04)00613-5

27. Li H, Zhang Q, Xu L, Chen Y, Wei Y, Zhou G. Factors predictive of prognosis after esophagectomy for squamous cell cancer. J Thorac Cardiovas sur. 2009; 1371:55–9. https://doi.org/10.1016/j.jtcvs.2008.05.024

28. Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation Therapy and...
Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database. PloS one. 2016;117:e0158916.

https://doi.org/10.1371/journal.pone.0158916

29. Hayashi Y, Iijima H, Isohashi F, et al. The heart’s exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: retrospective cohort study. BMC Cancer. 2019; 191:195. https://doi.org/10.1186/s12885-019-5421-y

30. Fernandes A, Berman AT, Mick R, et al. A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer. Int J Rad Oncol. 2016; 951:483–7. https://doi.org/10.1016/j.ijrobp.2015.12.005

31. Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Rad Oncol 2012; 835:1580–6. https://doi.org/10.1016/j.ijrobp.2011.10.053

32. Amin RN, Parikh SJ, Gangireddy VG, Kanneganti P, Talla S, Daram S. Early Esophageal Cancer Specific Survival Is Unaffected by Anatomical Location of Tumor: A Population-Based Study. Canadian J gastroenterol hepatol. 2016; 2016:6 132 640. https://doi.org/10.1155/2016/6132640.

33. Ercisli M., Lechun, G, Azeez S, Hamasalih R, Song S, Aziziaram Z. Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients. Cell Mol Biomed Rep 2021; 1(1): 33-41.

34. Kazemi E, Kahrizi D, Moradi MT, Sohrabi M, Yari K. Gastric cancer and helicobacter pylori: impact of hopQII gene. Cell Mol Biol 2016; 62(2):107-110.

35. Kazemi E, Kahrizi D, Moradi MT, Sohrabi M, Amini S, Mousavi SA, Yari K. Association between Helicobacter pylori hopQI genotypes and human gastric cancer risk. Cell Mol Biol 2016;62(1):6-9.

36. Kazemi E, Kahrizi D. Lack of association between gastric cancer and hopq alleles in Helicobacter pylori. Genetika. 2016;48(3):893-902.

37. Ismailli A, Yari K, Moradi MT, Sohrabi M, Kahrizi D, Kazemi E, Souri Z. IL-1B (C+ 3954T) gene polymorphism and susceptibility to gastric cancer in the Iranian population. Asian Pac J Cancer Prev 2015;16(2):841-4.

38. Kazemi E, Zargooshi J, Kaboudi M, Heidari P, Kahrizi D, Mahaki B, Mohammadian Y, Khazaei H, Ahmed K. A genome-wide association study to identify candidate genes for erectile dysfunction. Brief Bioinforma 2021; 22(4):bbaa338. https://doi.org/10.1093/bib/bbaa338
Table 1. Clinicopathologic Features of Esophageal Cancer Patients

| Variables                        | Alive (n = 4015) | Cancer-specific mortality (n = 19770) | Cardiovascular mortality (n = 1367) | Other mortalities (n = 3932) | Total (n = 29084) |
|----------------------------------|------------------|--------------------------------------|-----------------------------------|-----------------------------|------------------|
| Age                              | 61.77 (10.181)   | 63.93 (10.65)                        | 67.65 (9.612)                     | 64.26 (10.493)              | 63.84 (10.579)   |
| Sex                              |                  |                                      |                                   |                             |                  |
| Male                             | 3209 (79.9)      | 15893 (80.4)                         | 1088 (79.6)                       | 3164 (80.5)                | 23354 (80.3)     |
| Female                           | 806 (20.1)       | 3877 (19.6)                          | 279 (20.4)                        | 768 (19.5)                 | 573 (19.7)       |
| Marital status                   |                  |                                      |                                   |                             |                  |
| Single                           | 584 (14.5)       | 3067 (15.5)                          | 177 (12.9)                        | 613 (15.6)                 | 4441 (15.3)      |
| Married                          | 2758 (68.7)      | 11812 (59.7)                         | 818 (59.8)                        | 2406 (61.2)                | 17794 (61.2)     |
| Other                            | 673 (16.8)       | 4891 (24.7)                          | 372 (27.2)                        | 913 (23.2)                 | 6849 (23.5)      |
| Race                             |                  |                                      |                                   |                             |                  |
| White                            | 3538 (88.1)      | 16354 (82.7)                         | 1141 (83.5)                       | 3322 (84.5)                | 24355 (83.7)     |
| Black                            | 241 (6)          | 2336 (11.8)                          | 176 (12.9)                        | 441 (11.2)                 | 3194 (11)        |
| Other                            | 236 (5.9)        | 1080 (5.5)                           | 50 (3.7)                          | 169 (4.3)                  | 1535 (5.3)       |
| Type                             |                  |                                      |                                   |                             |                  |
| Squamous cell carcinoma          | 959 (23.9)       | 6965 (35.2)                          | 536 (39.2)                        | 1217 (31)                  | 9677 (33.3)      |
| Adenocarcinoma                   | 2770 (69)        | 11041 (55.8)                         | 743 (54.4)                        | 2338 (59.5)                | 16892 (58.1)     |
| Other                            | 286 (7.1)        | 1764 (8.9)                           | 88 (6.4)                          | 377 (9.6)                  | 2515 (8.6)       |
| Site                             |                  |                                      |                                   |                             |                  |
| Upper third of esophagus         | 178 (4.4)        | 1173 (5.9)                           | 76 (5.6)                          | 221 (5.6)                  | 1648 (5.7)       |
| Middle third of esophagus        | 595 (14.8)       | 4457 (22.5)                          | 324 (23.7)                        | 768 (19.5)                 | 6144 (21.1)      |
| Lower third of esophagus         | 3242 (80.7)      | 14140 (71.5)                         | 967 (70.7)                        | 2943 (74.8)                | 21292 (73.2)     |
| Grade                            |                  |                                      |                                   |                             |                  |
| I                                | 446 (11.1)       | 873 (4.4)                            | 134 (9.8)                         | 293 (7.5)                  | 1746 (6)         |
| II                               | 1911 (47.6)      | 7448 (37.7)                          | 602 (44)                          | 1600 (40.7)                | 11561 (39.8)     |
| III                              | 1591 (39.6)      | 10928 (55.3)                         | 593 (43.4)                        | 1923 (48.9)                | 15035 (51.7)     |
| IV                               | 67 (1.7)         | 521 (2.6)                            | 38 (2.8)                          | 116 (3)                    | 742 (2.6)        |
| Stage                            |                  |                                      |                                   |                             |                  |
| Localized                        | 1659 (41.3)      | 3480 (17.6)                          | 591 (43.2)                        | 1141 (29)                  | 6871 (23.6)      |
|          | Regional | Distant |  Chemotherapy | Radiation | Surgery | Sequence |
|----------|----------|---------|---------------|-----------|---------|----------|
|          | 1827 (45.5) | 7384 (37.3) | 533 (39) | 1475 (37.5) | 11219 (38.6) |
|          | 529 (13.2) | 8906 (45) | 243 (17.8) | 1316 (33.5) | 10994 (37.8) |
| Chemotherapy |          |         |             |           |         |          |
| No       | 1352 (33.7) | 7379 (37.3) | 632 (46.2) | 1650 (42) | 11013 (37.9) |
| Yes      | 2663 (66.3) | 12391 (62.7) | 735 (53.8) | 2282 (58) | 18071 (62.1) |
| Radiation |          |         |             |           |         |          |
| No       | 1576 (39.3) | 7916 (40) | 588 (43) | 1801 (45.8) | 11881 (40.9) |
| Yes      | 2439 (60.7) | 11854 (60) | 779 (57) | 2131 (54.2) | 17203 (59.1) |
| Surgery  |          |         |             |           |         |          |
| No       | 1005 (25) | 13110 (66.3) | 662 (48.4) | 2107 (53.6) | 16884 (58.1) |
| Yes      | 3010 (75) | 6660 (33.7) | 705 (51.6) | 1825 (46.4) | 12200 (41.9) |
| Sequence |          |         |             |           |         |          |
| No radiation and/or cancer-directed surgery | 2310 (57.5) | 15657 (79.2) | 1045 (76.4) | 3032 (77.1) | 22044 (75.8) |
| Radiation prior to surgery | 1400 (34.9) | 2379 (12) | 194 (14.2) | 573 (14.6) | 4546 (15.6) |
| Radiation after surgery | 254 (6.3) | 1599 (8.1) | 118 (8.6) | 302 (7.7) | 2273 (7.8) |
| Radiation before and after surgery | 42 (1) | 126 (0.6) | 10 (0.7) | 22 (0.6) | 200 (0.7) |
| Surgery both before and after radiation | 9 (0.2) | 9 (0.1) | 0 (0) | 3 (0.1) | 21 (0.1) |

All data are presented as n (%) except age presented as mean (standard deviation).
P-value of all variables were significant (< 0.001) except sex was non-significant (= 0.811).
Table 2. Risk Analysis on the Cancer-specific Mortality and Cardiovascular Mortality

| Variables                        | Univariate analysis       | Multivariate analysis       |
|----------------------------------|---------------------------|-----------------------------|
|                                  | Cancer-specific Mortality | Cardiovascular Mortality    | Regression Coefficient | Cardiovascular Mortality | Regression Coefficient |
|                                  | HR (95% CI)               | HR (95% CI)                 |                          | HR (95% CI)              |                          |
| Age, reference (< 65)            |                           |                             |                          |                          |                           |
| ≥ 65                             | 1.158 (1.126-1.191)       | 1.308 (1.167-1.467)         |                          | 1.1 (1.068-1.133)        | 0.096                      |
|                                  |                           | 1.1 (1.068-1.133)           |                          | 1.377 (1.219-1.556)      | 0.32                      |
| Sex, reference (Male)            |                           |                             |                          |                          |                           |
| Female                           | 1.034 (0.998-1.071)       | 0.856 (0.75-0.977)          | 0.923 (0.889-0.959)      | -0.08                    | 0.779 (0.672-0.903)       | -0.25                    |
| Marital status, reference        |                           |                             |                          |                          |                           |
| Single                           |                           |                             |                          |                          |                           |
| Married                          | 0.822 (0.79-0.856)        | 0.829 (0.705-0.976)         | 0.909 (0.872-0.947)      | -0.096                   | 0.799 (0.676-0.945)       | -0.224                   |
| Other                            | 0.985 (0.942-1.031)       | 1.022 (0.855-1.223)         | 0.977 (0.933-1.024)      | -0.023                   | 0.944 (0.784-1.137)       | -0.058                   |
| Race, reference (White)          |                           |                             |                          |                          |                           |
| Black                            | 1.191 (1.141-1.244)       | 1.062 (0.906-1.245)         | 1.094 (1.042-1.148)      | 0.09                     | 1.03 (0.863-1.231)        | 0.03                     |
| Other                            | 1.108 (1.042-1.179)       | 1.141 (0.859-1.514)         | 1.034 (0.971-1.102)      | 0.034                    | 1.017 (0.757-1.365)       | 0.017                    |
| Type, reference (Squamous cell carcinoma) |               |                             |                          |                          |                           |
| Adenocarcinoma                   | 0.881 (0.855-0.908)       | 1.123 (1.004-1.256)         | 0.912 (0.877-0.949)      | -0.092                   | 1.154 (1.001-1.331)       | 0.143                    |
| Other                            | 1.054 (1-1.11)            | 1.055 (0.842-1.322)         | 1.018 (0.961-1.078)      | 0.017                    | 1.061 (0.83-1.357)        | 0.059                    |
| Site, reference (Upper third of esophagus) |         |                             |                          |                          |                           |
| Middle third of esophagus        | 0.998 (0.936-1.064)       | 0.792 (0.616-1.018)         | 1.028 (0.964-1.097)      | 0.028                    | 0.967 (0.749-1.248)       | -0.033                   |
| Lower third of esophagus         | 0.917 (0.864-0.973)       | 0.739 (0.585-0.935)         | 1.004 (0.941-1.071)      | 0.004                    | 0.871 (0.676-1.121)       | -0.138                   |
| Grade, reference (I)             |                           |                             |                          |                          |                           |
| II                               | 1.103 (1.028-1.183)       | 1.398 (1.158-1.687)         | 1.063 (0.991-1.14)       | 0.061                    | 1.247 (1.029-1.512)       | 0.221                    |
| III                              | 1.314 (1.227-1.408)       | 1.481 (1.227-1.787)         | 1.253 (1.169-1.343)      | 0.225                    | 1.252 (1.029-1.522)       | 0.224                    |
| IV                               | 1.314 (1.178-1.464)       | 1.018 (0.709-1.46)          | 1.2 (1.74-1.34)          | 0.182                    | 0.868 (0.591-1.276)       | -0.141                   |
| Stage, reference (Localized) | Regional | Regional | Regional | Regional | Regional | Regional |
|-----------------------------|----------|----------|----------|----------|----------|----------|
| 1.185 (1.138-1.234) | 1.366 (1.214-1.537) | 1.467 (1.407-1.529) | 0.383 | 1.579 (1.393-1.791) | 0.457 |
| Distant | 2.083 (2-2.168) | 2.415 (2.073-2.813) | 1.981 (1.896-2.07) | 0.684 | 2.004 (1.687-2.381) | 0.695 |
| Chemotherapy, reference (No) | Yes | 0.678 (0.659-0.698) | 0.953 (0.857-1.061) | 0.5 (0.483-0.518) | -0.693 | 0.508 (0.436-0.592) | -0.678 |
| Radiation, reference (No) | Yes | 0.76 (0.739-0.782) | 0.993 (0.891-1.106) | 0.743 (0.716-0.772) | -0.297 | 0.532 (0.441-0.641) | -0.631 |
| Surgery, reference (No) | Yes | 0.512 (0.496-0.528) | 0.467 (0.418-0.521) | 0.383 (0.365-0.402) | -0.96 | 0.208 (0.17-0.255) | -1.569 |
| Sequence, reference (No) | Radiation prior to surgery | 0.553 (0.529-0.577) | 0.706 (0.605-0.823) | 1.72 (1.612-1.834) | 0.542 | 3.14 (2.422-4.07) | 1.144 |
| Radiation after surgery | 0.671 (0.637-0.706) | 0.696 (0.575-0.842) | 1.368 (1.285-1.457) | 0.313 | 2.201 (1.687-2.873) | 0.789 |
| Radiation before and after surgery | 0.542 (0.455-0.646) | 0.522 (0.28-0.975) | 1.763 (1.47-2.114) | 0.567 | 1.987 (1.026-3.85) | 0.687 |
| Surgery both before and after radiation | 0.68 (0.354-1.307) | - | 2.456 (1.275-4.732) | 0.899 | - | - |

CI = confidence interval; HR = hazard ratio.

*P < 0.05. *P < 0.01. *P < 0.001